| 姜 秀,赵文辉.CDK4/6抑制剂在乳腺癌中的研究进展[J].中国肿瘤,2017,26(2):125-129. |
| CDK4/6抑制剂在乳腺癌中的研究进展 |
| Research Progress of Application of CDK4/6 Inhibitors in Breast Cancer |
| 投稿时间：2016-04-26 |
| DOI：10.11735/j.issn.1004-0242.2017.02.A010 |
|
 |
| 中文关键词: 乳腺癌 HR+ CDK4/6抑制剂 survivin p16 |
| 英文关键词:breast cancer HR+ CDK4/6 inhibitors survivin p16 |
| 基金项目: |
|
| 摘要点击次数: 2608 |
| 全文下载次数: 757 |
| 中文摘要: |
| 摘 要：细胞周期的失调是肿瘤生长和转移的典型标志之一，通过CDK抑制剂重新建立细胞周期的调控在肿瘤靶向治疗的发展中已经成为有吸引力的方向。三种选择性靶向CDK4/6的口服药物已经被研发：palbociclib、abemaciclib和LEE011。当前的研究表明CDK4/6抑制剂与内分泌药物联合治疗激素受体阳性乳腺癌是一个新的标准。全文就细胞周期调控、乳腺癌中cyclinD-CDK4/6-Rb途径及相关蛋白p16和survivin的异常表现、CDK4/6抑制剂的相关临床试验及其结果进行总结。 |
| 英文摘要: |
| Abstract：Dysregulation of cell cycle is one of the typical signs of tumor growth and metastasis，re-establishing cell cycle control through CDK inhibitors has become an attractive direction in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib，abemaciclib and LEE011. Current researches indicate that CDK4/6 inhibitors combined with endocrine therapy is a new therapeutic approach for hormone receptor-positive breast cancer. The cell cycle regulation，abnormalities of cyclinD-CDK4/6-Rb pathway and the related p16 and survivin in breast cancer and the results of CDK4/6 inhibitors in clinical trials are summarized in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |